Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact ...
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback